Serial and quantitative analysis of mixed hematopoietic chimerism by PCR in patients with acute leukemias allows the prediction of relapse after allogeneic BMT
- PMID: 9535041
- DOI: 10.1038/sj.bmt.1701119
Serial and quantitative analysis of mixed hematopoietic chimerism by PCR in patients with acute leukemias allows the prediction of relapse after allogeneic BMT
Abstract
Within a prospective study we analyzed hematopoietic chimerism in serial peripheral blood samples taken from 55 patients with acute leukemias (ALL 21, AML 20, MDS 14) with a median age of 13.5 years at very short time intervals following allogeneic bone marrow transplantation (allo-BMT). The investigation was performed to determine the implications of mixed hematopoietic chimerism (MC) with regard to the clinical outcome in patients with acute leukemias after allo-BMT. Analysis of chimerism was performed by PCR of variable number of tandem repeat (VNTR) sequences with a maximum sensitivity of 0.8%. Thirteen male patients transplanted with the marrow of a female donor were also studied by amplification of a Y-chromosome-specific alphoid repeat (0.1-0.01% sensitivity). VNTR analysis in 55 patients revealed complete chimerism (CC) in 36 cases, MC in 18 follow-ups and autologous recovery in one patient. Quantitative analysis of MC identified 10/18 patients with increasing autologous patterns in whom 9/10 subsequently relapsed. The patient with autologous recovery relapsed as well. Eight of 18 patients with MC showed decreasing amounts of autologous DNA and became CC upon further follow-up. In contrast, only 7/36 patients with CC in the prior analysis of chimerism status relapsed. However, in 4/7 patients the interval between last CC confirmation and relapse was more than 4 months. In 2/7 patients autologous DNA was not detectable in peripheral blood but in bone marrow aspirates. One of these seven patients developed a fulminant relapse within 3 weeks. The probability of relapse-free survival for patients with CC is 0.67 (n = 36), for patients with decreasing MC 1.0 (n = 8) and for patients with increasing MC 0.1 (n = 10). In summary, the results demonstrate that serial and quantitative chimerism analysis at short time intervals by PCR provides a reliable and rapid screening method for the early detection of recurrence of underlying disease and is therefore a prognostic tool to identify patients at highest risk of relapse.
Similar articles
-
Prognostic value of hematopoietic chimerism in patients with acute leukemia after allogeneic bone marrow transplantation: a prospective study.Bone Marrow Transplant. 2000 Aug;26(3):327-32. doi: 10.1038/sj.bmt.1702504. Bone Marrow Transplant. 2000. PMID: 10967574 Clinical Trial.
-
Mixed hematopoietic chimerism after allogeneic bone marrow transplantation: the impact of quantitative PCR analysis for prediction of relapse and graft rejection in children.Bone Marrow Transplant. 1997 Apr;19(7):697-702. doi: 10.1038/sj.bmt.1700721. Bone Marrow Transplant. 1997. PMID: 9156247
-
Quantitative analysis of chimerism after allogeneic stem cell transplantation by real-time polymerase chain reaction with single nucleotide polymorphisms, standard tandem repeats, and Y-chromosome-specific sequences.Am J Hematol. 2006 Oct;81(10):735-46. doi: 10.1002/ajh.20693. Am J Hematol. 2006. PMID: 16838323
-
Establishment of complete and mixed donor chimerism after allogeneic lymphohematopoietic transplantation: recommendations from a workshop at the 2001 Tandem Meetings of the International Bone Marrow Transplant Registry and the American Society of Blood and Marrow Transplantation.Biol Blood Marrow Transplant. 2001;7(9):473-85. doi: 10.1053/bbmt.2001.v7.pm11669214. Biol Blood Marrow Transplant. 2001. PMID: 11669214 Review.
-
Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.Dan Med Bull. 2007 May;54(2):112-39. Dan Med Bull. 2007. PMID: 17521527 Review.
Cited by
-
CD19+ lineage chimerism, an early biomarker after anti-CD19 CAR-T cell therapy in patients previously receiving a hematopoietic stem cell transplantation.Front Immunol. 2022 Aug 8;13:960412. doi: 10.3389/fimmu.2022.960412. eCollection 2022. Front Immunol. 2022. PMID: 36003375 Free PMC article.
-
Pharmacologic Strategies for Post-Transplant Maintenance in Acute Myeloid Leukemia: It Is Time to Consider!Cancers (Basel). 2022 Mar 15;14(6):1490. doi: 10.3390/cancers14061490. Cancers (Basel). 2022. PMID: 35326641 Free PMC article. Review.
-
Lineage-specific early complete donor chimerism and risk of relapse after allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia.Bone Marrow Transplant. 2022 May;57(5):753-759. doi: 10.1038/s41409-022-01615-8. Epub 2022 Feb 24. Bone Marrow Transplant. 2022. PMID: 35210563 Free PMC article.
-
Early Reconstitution of Antibody Secreting Cells after Allogeneic Stem Cell Transplantation.J Clin Med. 2022 Jan 5;11(1):270. doi: 10.3390/jcm11010270. J Clin Med. 2022. PMID: 35012014 Free PMC article.
-
Treatment of AML Relapse After Allo-HCT.Front Oncol. 2021 Dec 16;11:812207. doi: 10.3389/fonc.2021.812207. eCollection 2021. Front Oncol. 2021. PMID: 34976845 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous
